Last reviewed · How we verify
L-Phenylalanine (PHENYLALANINE)
L-Phenylalanine is a small molecule drug that targets the probable G-protein coupled receptor 139. It belongs to the phenylalanine class and its mechanism of action is not well established. The commercial status of L-Phenylalanine is unknown, and it has not been approved by the FDA for any indications. Further research is needed to determine its efficacy and safety profile. As a result, there is limited information available on its half-life, bioavailability, and generic manufacturers.
At a glance
| Generic name | PHENYLALANINE |
|---|---|
| Target | Intestinal-type alkaline phosphatase, Large neutral amino acids transporter small subunit 1, E3 ubiquitin-protein ligase XIAP |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Nausea
- Pyrexia
- Hypertension
- Vomiting
- Hemoglobin decreased
- Protein total decreased
- Hypokalemia
- Blood potassium decreased
- Gamma-glutamyltransferase increased
- Hyperglycemia
- Blood alkaline phosphatase increased
- Blood calcium decreased
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Metabolic Effects of the Exercise-metabolite Lac-Phe (NA)
- Cortical Electrophysiology of Response Inhibition in Parkinson's Disease (PHASE4)
- Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery (PHASE1)
- Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-Phenylalanine CI brief — competitive landscape report
- L-Phenylalanine updates RSS · CI watch RSS